29 citations
,
July 2019 in “Dermatologic Therapy” Dupilumab can both heal and cause hair loss.
2 citations
,
March 2010 in “Acta Biochimica Polonica” Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.
April 2025 in “Russian Pediatric Journal” PRP therapy shows promise for healing in kids but needs more research.
October 2022 in “Portuguese journal of dermatology and venereology” Dupilumab led to complete hair regrowth and improved skin condition in a young man with severe eczema and hair loss.
October 2022 in “Zenodo (CERN European Organization for Nuclear Research)” Combining PDLLA and PRP effectively reduces wrinkles and improves skin quality.
January 2024 in “Wiadomości Lekarskie” AI and new therapies show promise in medicine, especially for cancer and regenerative treatments.
January 2017 in “Hair transplant forum international” Platelet-rich plasma (PRP) treatments are not effective.
20 citations
,
August 2010 in “The Journal of Urology” Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.
July 2023 in “Assiut Veterinary Medical Journal/Maǧallaẗ Asyūṭ al-ṭibiyyaẗ al-baytariyyaẗ” Antiandrogens help improve developmental delays caused by valproic acid in rats.
Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.
October 2022 in “Biomolecules” Allopregnanolone can reduce gut inflammation and normalize neurotransmitter levels after finasteride withdrawal.
Platelet-rich plasma treatment significantly improved hair density and regrowth in both men and women suffering from pattern hair loss, with even better results when combined with certain medications.
June 2023 in “GLOBAL JOURNAL FOR RESEARCH ANALYSIS” PRP is a promising treatment for hair loss.
15 citations
,
May 2020 in “Journal of Dermatological Treatment” PRP treatment increases hair density and thickness in androgenetic alopecia by 79%.
29 citations
,
October 2009 in “Pharmacology Biochemistry and Behavior” July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
Standardized PRP therapy can improve treatment for hair loss.
39 citations
,
March 2019 in “Dermatologic Surgery” PRP therapy increases hair density for androgenetic alopecia.
PRP therapy is a simple and safe option for hair loss, but its effectiveness is not clearly stated.
December 2015 in “Vascular Pharmacology” Different cells affect hair follicle blood vessels, endothelial cells react differently to inflammation and oxidized fats, and prasugrel better protects heart vessels during a procedure than clopidogrel.
42 citations
,
January 2019 in “Frontiers in Immunology” A blood pressure drug, diltiazem, may also help treat influenza.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” PRP therapy can improve hair growth in early to moderate hair loss but needs standardized methods for consistent results.
37 citations
,
October 2014 in “JAMA dermatology” A woman with severe hair loss was successfully treated with the drug adalimumab.
March 2025 in “SKIN The Journal of Cutaneous Medicine” 2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
52 citations
,
May 2011 in “Journal of Neuroendocrinology” PEA boosts allopregnanolone production and reduces oxidative stress in brain cells.
3 citations
,
July 2024 in “Cureus” Platelet-rich plasma (PRP) shows promise for treating melasma but needs more research for confirmation.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
April 2025 in “Health Science Reports” PRP treatment improved skin pigmentation and appearance in facial lichen planus pigmentosus.